Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celyad Oncology SA - American Depositary Shares (NQ:CYAD)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 18, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Celyad Oncology SA - American Depositary Shares

< Previous 1 2 3 4 5 Next >
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
From Celyad Oncology SA
Via GlobeNewswire
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology announces receipt of Nasdaq delisting notice
From Celyad Oncology SA
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology reports first quarter 2023 financial results and recent business highlights
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price
From Celyad Oncology SA
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Celyad Oncology announces receipt of Nasdaq notice
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology appoints Georges Rawadi as its new CEO
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology reports full year 2022 financial results and recent business highlights
From Celyad Oncology SA
Via GlobeNewswire
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
Celyad Oncology to announce full year 2022 financial results and host conference call
From Celyad Oncology SA
Via GlobeNewswire
Why Titan Machinery Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) shares jumped 40.2% to $2.5109 after the company announced the successful completion of a Phase 2A clinical trial evaluating the safety and efficacy... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers ThermoGenesis Holdings, Inc. (NASDAQ: THMO) shares jumped 80% to $3.7820 after the company announced the roll out of ReadyStart cGMP Suites for early-stage cell and gene-therapy companies. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Jounce Therapeutics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're beginning the day with a look at the biggest pre-market stock movers traders need to know about for Wednesday morning! 
Via InvestorPlace
Celyad Oncology announces non-cash impairment
From Celyad Oncology SA
Via GlobeNewswire
REPEAT -- Celyad Oncology SA - Letter to Shareholders
From Celyad Oncology SA
Via GlobeNewswire
Celyad Oncology SA - Letter to Shareholders
From Celyad Oncology SA
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Universal Electronics Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Ibio Inc (NYSE: IBIO) shares rose 97% to $1.4787 after the company announced MUC16 as its latest immune-oncology target program. 
Via Benzinga
Celyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01
From Celyad Oncology SA
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.